The Borneo Post

New plant to push Duopharma to the fore of effervesce­nt manufactur­ing

-

KUCHING: CCM Duopharma Biotech Bhd (Duopharma) expects its newly completed Effervesce­nt plant in Bangi to put the company at the forefront of technology developmen­t in manufactur­ing high-quality pharmaceut­ical products using effervesce­nt technology that offers advantages over convention­al manufactur­ing of healthcare products.

The RM7 million effervesce­nt plant – the country’s first ever such facility and commission­ed in October 2017 – has the capability to produce 107 million tablets of Flavettes Effervesce­nt Vitamin C annually.

Through the latest investment, Duopharma expects to roll out various effervesce­nt products under the Company’s current range of award winning OTC brands, such as Flavettes, Champs, Proviton and Uphamol.

This range of products will provide consumers with a choice of a new delivery format for health supplement­s, which is seen to be a preferred trend in the market.

In November 2017, Duopharma launched four new Effervesce­nt products under the Flavettes brand, and this range of Vitamin C products has been well accepted by the market, with an overwhelmi­ng demand.

Speaking at a media familiaris­ation trip to the plant, Duopharma group managing director Leonard Ariff Abdul Shatar said that Duopharma’s latest production facility is part of the Company’s Manufactur­ing Optimisati­on Strategy (MOS) which includes rationalis­ing and upgrading its facilities to accelerate growth.

“There is a great demand for Effervesce­nt pharmaceut­ical products, especially Flavettes Effervesce­nt Vitamin C, in the market as they offer many functional benefits to consumers including providing a much easier way to ingest supplement­s instead of having to swallow a tablet, and giving a pleasant taste compared to regular tablets.

“As a leading pharmaceut­ical company in Malaysia, Duopharma strives to be at the vanguard of new technology as we constantly explore ways to enhance our customer experience.

“Formulatin­g and manufactur­ing Effervesce­nt products requires specialise­d knowledge and technologi­cal skill with an excellent environmen­tal infrastruc­ture to control the temperatur­e and humidity of the production facility to ensure optimal product stability,” said Leonard Ariff.

Effervesce­nt technology enables tablets to dissolve into a solution once they are in contact with water. This allows active ingredient­s to dissolve completely and evenly as well as to absorb quicker into the bloodstrea­m compared to convention­al formulatio­ns, resulting in faster onset of action.

 ??  ?? Duopharma’s latest production facility is part of the company’s Manufactur­ing Optimisati­on Strategy (MOS) which includes rationalis­ing and upgrading its facilities to accelerate growth.
Duopharma’s latest production facility is part of the company’s Manufactur­ing Optimisati­on Strategy (MOS) which includes rationalis­ing and upgrading its facilities to accelerate growth.

Newspapers in English

Newspapers from Malaysia